Overcoming obesity: Weight-loss drugs are underused

REFERENCES

1. ↵
   1. Pilitsi E,
   2. Farr OM,
   3. Polyzos SA, et al

   . Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism 2019; 92:170–192. doi:10.1016/j.metabol.2018.10.010

   OpenUrlCrossRefPubMed
2. ↵
   1. Kang JG,
   2. Park CY

   . Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 2012; 36(1):13–25. doi:10.4093/dmj.2012.36.1.13

   OpenUrlCrossRefPubMed
3. ↵
   1. Feingold KR,
   2. Anawalt B,
   3. Boyce A et al.

   1. Kumar RB,
   2. Aronne L

   . Pharmacologic treatment of obesity. In: Feingold KR, Anawalt B, Boyce A et al., eds. Endotext. South Dartmouth, MA: MDText.com, Inc; 2000–2020.
4. ↵
   1. Semla TP,
   2. Ruser C,
   3. Good CB, et al

   . Pharmacotherapy for weight management in the VHA. J Gen Intern Med 2017; 32(suppl 1):70–73. doi:10.1007/s11606-016-3949-y

   OpenUrlCrossRef
5. ↵
   1. Chan RS,
   2. Woo J

   . Prevention of overweight and obesity: how effective is the current public health approach. Int J Environ Res Public Health 2010; 7(3):765–783. doi:10.3390/ijerph7030765

   OpenUrlCrossRefPubMed
6. ↵
   1. Puhl RM,
   2. Heuer CA

   . The stigma of obesity: a review and update. Obesity (Silver Spring) 2009; 17(5):941–964. doi:10.1038/oby.2008.636

   OpenUrlCrossRefPubMed
7. ↵
   1. Onakpoya IJ,
   2. Heneghan CJ,
   3. Aronson JK

   . Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med 2016; 14(1):191. doi:10.1186/s12916-016-0735-y

   OpenUrlCrossRef
8. ↵
   1. Hendricks EJ

   . Off-label drugs for weight management. Diabetes Metab Syndr Obes 2017; 10:223–234. doi:10.2147/DMSO.S95299

   OpenUrlCrossRef
9. ↵
   1. Gomez G,
   2. Stanford FC

   . US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes (Lond) 2018; 42(3):495–500. doi:10.1038/ijo.2017.287

   OpenUrlCrossRef
10. ↵
    1. Veerman JL,
    2. Barendregt JJ,
    3. Forster M,
    4. Vos T

    . Cost-effectiveness of pharmacotherapy to reduce obesity. PLoS One 2011; 6(10):e26051. doi:10.1371/journal.pone.0026051

    OpenUrlCrossRefPubMed
11. ↵
    1. US Congress

    . S.595—Treat and Reduce Obesity Act of 2019. Accessed July 30, 2020. https://www.congress.gov/bill/116th-congress/senate-bill/595/text
12. ↵
    1. Burguera B,
    2. Schauer P,
    3. Kahan S

    . What to offer the 99% of patients with severe obesity who do not undergo bariatric surgery? Mayo Clin Proc 2019; 94(6):957–960. doi:10.1016/j.mayocp.2018.11.020

    OpenUrlCrossRef